Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis

作者：Kellett Fiona^*; Robert Niven M

来源：Respiratory Medicine, 2011, 105(12): 1831-1835.

DOI：10.1016/j.rmed.2011.07.019

• Hypertonic saline
• Lung function
• Quality of life
• Bronchiectasis

Sputum retention is a distressing feature of non-cystic fibrosis bronchiectasis and has been shown to contribute to the vicious cycle of infection seen in this disease. In a previous study we demonstrated that nebulised 7% hypertonic saline was both safe and effective in this patient: population. Patients with a clinical diagnosis of non-cystic fibrosis bronchiectasis, confirmed by HRCT, were entered into a randomised single blind cross-over study to evaluate 0.9% sodium chloride (IS) and 7% hypertonic saline (HS). Following a 4 week run in patients received a random order active HS or IS daily for 3 months. A 4 week wash-out phase was included between phases. We report lung function, quality of life, and health care utilisation responses. 32 patients mean age 56.6 years (SD 14.6), 16 male, were recruited of which 28 were randomised and completed the study. Lung %change from baseline) improved in HS vs. IS (FEVi: 15.1, 1.8 p <0.01; FVC: 11.2, 0.7 p <0.01. SGRQ improved significantly from baseline (HS 6.0, IS 1.2; p <0.05). There were reductions in annualised antibiotic usage (HS 2.4, IS 5.4 courses per patient per year), annualised emergency health care utilisation visits were reduced (HS 2.1, IS 4.9 events per patient per year). There were also improvements in sputum viscosity and ease of expectoration (visual analogue scale). Regular use of 7% hypertonic saline improves lung function, quality of life and health care utilisation in non-cystic fibrosis bronchiectasis patients.

• 出版日期2011-12